medigraphic.com

2017, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2017; 18 (2)

Current trends of the use of statins for dyslipidemias and other extra lipid effects

Fleitas EAS

Language: Spanish
References: 51
Page: 178-191
PDF size: 87.58 Kb.


ABSTRACT

Introduction: Patients with acute atherosclerotic conditions usually present with moderate cholesterol concentrations together with low-density lipoprotein levels, which indicates the importance of the interactions with other risk factors. Statin therapy improves prognosis after the occurrence of an acute coronary syndrome, especially in intensive care and regardless of cholesterol values, which leads to consider this therapeutic strategy as an option to be extended to all the patients with a set vascular disease.
Objective: To examine the present tendencies in the statin therapy.
Data sourse: A literature review was made from 2010 to 2015 in MedLine Hinari, Cochrane and PubMed databases and in leading journals in the publication of topics and articles of interest.
Data synthesis: Statins are effective drugs to decrease the blood cholesterol and triglyceride levels. Besides, they increase the high density lipoprotein cholesterol and reduce the incidence of atherosclerotic cardiovascular disease, therefore, they are considered first-choice drugs for the treatment of atherogenic dyslipidemia. It has been proved that hypolipidemic treatment with statin avoids the progression of the disease into the acute stage.
Conclusions: The review provides an update on the fundamental role of statins in the treatment of patients with artheropathy. It is desirable to initiate the treatment as early as possible and to extend it to other arterial areas such as cerebrovascular and peripheral ones.


REFERENCES

  1. Reiner Z, Catapano A, De Backer G, Graham I, Taskinen M, Wiklund O, et al. ESC/EAS. Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769-818.

  2. Stone N, Robinson J, Lichtenstein A, Bairey-Merz C, Blum C, Eckel R, et al. 2013 ACC/AHA. Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl2):S1-S45. Accesss: 2015 Aug 22. Available at: http://circ.ahajournals.org/content/suppl/2013/11/07/01.cir.0000437738.63853.7a .DC1.html

  3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.

  4. Degano IR, Elosua R, Kaski JC, Fernandez-Berges DJ, Grau M, Marrugat J. Estabilidad de la placa aterosclerótica y la paradoja del sur de Europa. Rev Esp Cardiol. 2013;66:56-62.

  5. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/ EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.

  6. Alonso-Karlezi R, Mata N, Mata P. Control de las hiperlipemias en la práctica clínica. Rev Esp Cardiol Supl. 2006;6(G):24-35.

  7. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al. Benefit of early statintherapy in patients with acute myocardial infarction who have extremely low lowdensitylipoprotein cholesterol. J Am Coll Cardiol. 2011;58:1664-71.

  8. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.

  9. Rokitansky C Von. A manual of pathologic anatomy. London: New Sydenham Society; 1852.

  10. Stamler J. Epidemiología de la cardiopatía coronaria. Clin Med NA. 1973;1:5-46.

  11. Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012;110:307-13.

  12. Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant eff ects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol. 2014;10:140-7.

  13. Nissen S, Tuzcu M, Schoenhagen P, Brown G, Ganz P, Vogel R, et al; for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA. 2004;291:1071-80.

  14. Ballantyne C, Raichlen J, Nicholls S, Erbel R, Tardif JC, Brener S, et al. Effect of Rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of Rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458-66.

  15. Pintó X, Valdivielso P, Pérez de Juan JM, Plana N, Garcia-Arias C, Fuentes FJ, et al. Spanish registry of hypertriglyceridemia (Spanish Society of Arteriosclerosis, SAS). Predictive factors of achieving therapeutic goals of hypertriglyceridemia. Curr Med Res Opin. 2014;30:19-26.

  16. Gonzalez-Juanatey JR, Millan J, Alegria E, Guijarro C, Lozano JV, Vitale GC. Prevalencia y características de la dislipemia en pacientes en prevención primariay secundaria tratados con estatinas en España. Estudio DYSIS-España. Rev Esp Cardiol. 2011;64:286-94.

  17. Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. Atherosclerosis. 2014;232:410-3.

  18. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipidmodifyingefficacy of Rosuvastatin versus Atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012;109:1239-46.

  19. Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013;34:1818-25.

  20. Kim JW, Yun KH, Kim EK, Joe DY, Ko JS, Lee EM, et al. Effect of high dose Rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction. Korean Circ J. 2014;44:76-81.

  21. Halcox J, Deanfield J. Beyond the laboratory: clinical implications for statinpleiotropy. Circulation. 2004;109:II42-8.

  22. Zhou Q, Liao J. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467-78.

  23. Mihos C, Pineda A, Santana O. Cardiovascular effects of statins, beyond lipid lowering properties. Pharmacol Res. 2014;88:12-9.

  24. Dobesh P, Olsen K. Statins role in the prevention and treatment of sepsis. Pharmacol Res. 2014;88:31-40.

  25. Singh S, Singh P. Statin a day keeps cancer at bay. World J Clin Oncol. 2013;4:43-6.

  26. Opie L. Can dementia be lessened by statins? Lancet. 2014;384:953.

  27. Ray KK, Kastelein JJ, Matthijs Boekholdt S, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960-8.

  28. Utilización de medicamentos hipolipemiantes en España durante el periodo 2000-2012. Rev Española Cardiol. 2015;(2). Acceso: 13 Dic 2015. Disponible en: http://www.revespcardiol.org el 13/02/2015

  29. Cordero A, Moreno-Arribas J, Bertomeu-Gonzalez V, Agudo P, Miralles B, Masia MD, et al. Los niveles bajos de colesterol HDL se asocian de forma independiente a la enfermedad coronaria aguda en pacientes que ingresan por dolor torácico. Rev Esp Cardiol. 2012;65:319-25.

  30. Stokins B. Efectos pleiotrópicos de las estatinas. Rev Chil Cardiol. 2009;28:198- 201.

  31. Badimon L, Vilahur G. Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro? Rev Esp Cardiol Supl. 2011;11(B):3-13.

  32. Villalobos ME, Sánchez-Muniz FJ, Acin MT, Vaquero MP, Higueras FJ, Bastida S. Similitudes, diferencias y agonismos en los efectos pleiotrópicos de las estatinas y los ácidos grasos omega-3. Nutr Hosp. 2010;25:889-909.

  33. Palaniswamy C, Selvaraj D, Selvaraj T, Sukhija R. Mechanisms underlying pleiotropic effects of statins. Am J Ther. 2010;17:75-8.

  34. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55:2736-42.

  35. Cordero A, Bertomeu-Martínez V, Mazon P, Facila L, Cosin J, Bertomeu- Gonzalez V, et al. Patients with cardiac disease: Changes observed through last decade in outpatient clinics. World J Cardiol. 2013;5:288-94.

  36. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-62.

  37. Ridker PM, Cook NR. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71.

  38. Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.

  39. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.

  40. Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61:1041-51.

  41. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High dose Atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.

  42. Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D, et al, for the Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA. 2001;285:1711-8.

  43. Nicholls S, Ballantyne C, Barter P, Chapman J, Erbel R, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-87.

  44. Moon G, Kim S, Cho Y, Ryoo S, Bang O. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol. 2014;10:140-7.

  45. Fang W, Li H, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012;74:744-56.

  46. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disorders. 2012;12:107-13.

  47. Ma M, Uekawa K, Hasegawa Y, Nakagawa T, Katayama T, Sueta D, et al. Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain Res. 2013;1519:87-9.

  48. Darryl P. Treatments for alzheimer disease. South Med J. 2005;98(6):628- 35.Access: 1 Dic 2013. Disponible en: http://www.medscape.com/viewarticle/507361

  49. Abby B. Siegel MD. Use of statins in hepato cellular carcinoma. J. Gastroenterol Hepatol (NY). 2003 Aug;9(8):512-4.

  50. Leonarno A, Loria P. Potential for statins in the chemoprotection and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;(11):1654-64.

  51. Pejman G. Mansourian MD. Effects of statins on the risk of hepatocellular carcinoma. Gastroenterol Hepatol. 2014;10(7):417-26.




2020     |     www.medigraphic.com